Concurrent administration of inactivated hepatitis A vaccine with immune globulin in healthy adults

被引:18
作者
Walter, EB
Hornick, RB
Poland, GA
Tucker, R
Bland, CL
Clements, DA
Rhamstine, CC
Jacobson, RM
Brown, L
Gress, JO
Harris, KE
Wiens, BL
Nalin, DR
机构
[1] Duke Univ, Med Ctr, Dept Pediat, Vaccine & Infect Dis Epidemiol Unit, Durham, NC 27704 USA
[2] Orlando Reg Med Ctr, Med Educ Adm, Orlando, FL 32806 USA
[3] Mayo Clin & Mayo Fdn, Mayo Vaccine Res Grp, Rochester, MN 55905 USA
[4] Wenatchee Valley Clin, Div Infect Dis, Wenatchee, WA USA
[5] Merck Res Labs, W Point, PA 19486 USA
关键词
hepatitis A vaccine; immune globulin; hepatitis A virus;
D O I
10.1016/S0264-410X(98)00370-3
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
301 healthy adult volunteers were randomized to one of three treatment groups: inactivated hepatitis A vaccine alone; inactivated hepatitis A vaccine with immune globulin (IE) concurrently or Ig alone. The first two treatment groups received a second dose of hepatitis A vaccine at week 24. Anti-HAV was measured 4, 8, 12, 24 and 28 weeks after the primary immunization. When comparing subjects receiving inactivated hepatitis A vaccine alone to those receiving vaccine and Ig, the seropositivity rates were not significantly different at 4, 8, 12 and 28 weeks, but at week 24 the seropositivity rate was lower in the group receiving both vaccine and Ig compared to the group receiving vaccine alone (92.0% compared to 97.0%). At weeks 8, 12 and 24 the geometric mean titers (GMTs) were significantly lower for subjects receiving both vaccine and Ig. The GMTs were not significantly different after the second dose of vaccine. At all time points, the lower serum antibody concentrations observed in subjects receiving both inactivated hepatitis A vaccine and Ig were nevertheless substantially higher than the cutoff for assay seropositivity and much higher than after Ig alone; these differences are therefore clinically insignificant. (C) 1999 Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1468 / 1473
页数:6
相关论文
共 24 条
[1]   SAFETY, TOLERABILITY AND IMMUNOGENICITY OF A FORMALIN-INACTIVATED HEPATITIS-A VACCINE (VAQTA(R)) IN RURAL KENTUCKY CHILDREN [J].
BLOCK, SL ;
HEDRICK, JA ;
TYLER, RD ;
SMITH, RA ;
CALANDRA, G ;
PATTERSON, C ;
LEWIS, J ;
SITRIN, R ;
MILLER, W ;
SCHWARTZ, S ;
WIENS, B ;
NALIN, D .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1993, 12 (12) :976-980
[2]  
*CDC, 1995, MMWR-MORBID MORTAL W, V44, P559
[3]  
Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P1
[4]   PREVENTION OF ENDEMIC ICTERIC VIRAL-HEPATITIS BY ADMINISTRATION OF IMMUNE SERUM GAMMA-GLOBULIN [J].
CONRAD, ME ;
LEMON, SM .
JOURNAL OF INFECTIOUS DISEASES, 1987, 156 (01) :56-63
[5]  
EGAN LJ, 1993, P 1993 INT S VIR HEP, P106
[6]   SAFETY PROFILE AND IMMUNOGENICITY OF AN INACTIVATED VACCINE DERIVED FROM AN ATTENUATED STRAIN OF HEPATITIS-A [J].
ELLERBECK, EF ;
LEWIS, JA ;
NALIN, D ;
GERSHMAN, K ;
MILLER, WJ ;
ARMSTRONG, ME ;
DAVIDE, JP ;
RHOAD, AE ;
MCGUIRE, B ;
CALANDRA, G ;
PROVOST, PJ ;
MIDTHUN, K .
VACCINE, 1992, 10 (10) :668-672
[7]   THE USE OF HUMAN IMMUNE SERUM GLOBULIN (GAMMA GLOBULIN) - ININFECTIOUS (EPIDEMIC) HEPATITIS IN THE MEDITTERANEAN THEATER OF OPERATIONS .1. STUDIES ON PROPHYLAXIS IN 2 EPIDEMICS OF INFECTIOUS HEPATITIS [J].
GELLIS, SS ;
STOKES, J ;
BROTHER, GM ;
HALL, WM ;
GILMORE, HR ;
BEYER, E ;
MORRISSEY, RA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1945, 128 (15) :1062-1063
[8]   DEPRESSION OF THE IMMUNE-RESPONSE TO AN INACTIVATED HEPATITIS-A VACCINE ADMINISTERED CONCOMITANTLY WITH IMMUNE GLOBULIN [J].
GREEN, MS ;
COHEN, D ;
LERMAN, Y ;
SJOGREN, M ;
BINN, LN ;
ZUR, S ;
SLEPON, R ;
ROBIN, G ;
HOKE, C ;
BANCROFT, W ;
SAFARY, A ;
DANON, Y ;
WIENER, M .
JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (03) :740-743
[9]   PREVENTION OF INFECTIOUS HEPATITIS WITH GAMMA-GLOBULIN [J].
HAVENS, WP ;
PAUL, JR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1945, 129 (04) :270-272
[10]  
LEENTVAARKUIJPE.A, 1992, VACCINE S1, V10, P138